Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as a solution for intravenous use. It treats hemophilia A by providing the missing clotting protein in patients who require it. GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Octanate is a recombinant factor VIII product used within the coagulation cascade to manage bleeding disorders associated with hemophilia A.

- Hemophilia A (severe): Provides sustained clotting activity to prevent or control spontaneous bleeding episodes. - Hemophilia A (moderate): Supports routine prophylaxis to reduce the frequency of bleeding events. - Hemophilia A (mild): Used on‑demand to treat bleeding episodes when they occur. - Surgical prophylaxis: Enables adequate hemostasis during surgical procedures in patients with hemophilia A. - Peri‑peri   

Common  

Placeholder